Industry Overview - The nuclear medicine market is experiencing robust growth due to increasing health awareness and rapid advancements in medical technology [1] - As of July 4, 2024, 88 radioactive new drugs have been approved globally, with only 18 for treatment purposes [1] - From 2021 onwards, China's policies have strongly supported the nuclear medicine industry, which is expected to drive its development [1] - According to Ping An Securities, the nuclear medicine market in China is projected to grow from 5 billion yuan to 26 billion yuan at a CAGR of 26.6% from 2023 to 2030 [1] Company Highlights - Yuan Da Pharmaceutical (00512) is a notable player in the nuclear medicine sector, with a successful Phase II clinical trial for its global innovative product STC3141 [2] - CICC maintains profit forecasts for Yuan Da Pharmaceutical at 2.131 billion yuan for 2025 and 2.235 billion yuan for 2026 [2] - The company has received approval for its innovative drug ITM-11 to conduct Phase III clinical trials, targeting neuroendocrine tumors [3] - China Tongyuan (01763) is a leading enterprise in the nuclear medicine industry, dominating the market for radioactive pharmaceuticals and being the largest supplier of radiation source products in China [4] - In October 2023, China Tongyuan began mass production of a new dual-spiral CT radiation therapy platform, marking a significant advancement in domestic high-end radiation therapy products [4]

Company Overview - As of December 31, 2024, the company has established a network of 37 medical centers and 7 R&D and production bases, serving over 18,000 medical institutions and more than 60 million people annually[10]. - The company employs 3,367 staff as of December 31, 2024, and was listed on the Main Board of the Stock Exchange on July 6, 2018[7]. - The company has a stock code of 1763 and was listed on July 6, 2018[25]. - The company has appointed Ms. Wang Cangren and Ms. Kwan Sau In as joint company secretaries[22]. - The company’s auditor is Shinewing (HK) CPA Limited[22]. - The company has established various committees under the board, including the Audit and Risk Management Committee and the Science and Technology Innovation Committee[21]. Financial Performance - The company achieved an operating income of RMB 7.575 billion, representing a year-on-year increase of 14.2%[30]. - Total profit reached RMB 1.045 billion, reflecting a year-on-year increase of 13.3%[30]. - Net profit was RMB 880 million, also showing a year-on-year increase of 13.3%[30]. - As of December 31, total assets amounted to RMB 14.767 billion, with net assets totaling RMB 7.745 billion[33]. - The gearing ratio stood at 47.56%[33]. - For the year ended December 31, 2024, the company achieved revenue of RMB 7,574.8 million, representing a year-on-year increase of 14.2%[110]. - The net profit for the same period was RMB 879.5 million, reflecting a year-on-year increase of 13.3%, with net profit attributable to the parent company reaching RMB 406.6 million, up 9.6% year-on-year[110]. - The gross profit margin decreased to 48.6% from 52.5% in the previous year, while the operating profit margin slightly improved to 14.3%[106]. Market Position and Products - The company supplies over 40,000 sets of ancillary radioactive source equipment and has captured nearly 70% of the large-scale Class A radiotherapy equipment market in China, making it the leading brand in this category[10]. - CIRC is the largest manufacturer of imaging diagnostic and therapeutic radiopharmaceuticals in China, and the only service provider covering the entire process of irradiation stations[8]. - The company launched the sodium fluorine-18 injection, the first PET imaging agent approved for bone imaging in China, filling a market gap[114]. - The therapeutic sodium iodine-131 capsule's negotiated price was officially implemented, meeting more clinical needs[114]. - The Group's nuclear medical equipment and related services generated RMB1,223.0 million in revenue, marking a year-on-year growth of 31.0%[129]. Research and Development - In 2024, the company achieved a significant milestone with the completion of the first domestic production line for carrier-free lutetium-177 with an annual output of 10,000 curies and a production capacity of thousands of germanium-gallium generators, marking the capability for large-scale commercial production of these nuclides in China[35][36]. - The annual R&D investment reached RMB 660 million, representing a year-on-year increase of 3.3%, with an investment intensity of 8.6%[35][36]. - The company was granted 224 new patent authorizations in 2024, including 65 invention patents[35][43]. - The R&D team consists of 507 personnel focused on optimizing production technologies and developing new products, contributing to technological innovation across various industrial fields[165]. Strategic Initiatives - The company aims to enhance its core functions and competitiveness, focusing on the "6+N" industrial layout, which includes nuclides, nuclear medicines, and irradiation applications[11]. - The company is committed to providing integrated solutions for nuclear medicine and radiotherapy, contributing to the development of a "strong nuclear power nation" and a "healthy China"[7]. - The company is implementing the "Healthy China" strategy to enhance core functions and competitiveness[33]. - The company aims to stabilize growth, strengthen innovation, and promote reform in the nuclear healthcare sector[33]. - The Group aims to support the "Healthy China" strategy by providing integrated solutions for nuclear medicine and radiotherapy, enhancing healthcare delivery across the country[181]. International Expansion - The company won the bid for a million-curie gamma irradiation station project in Bangladesh, marking its first breakthrough in overseas government agency EPC projects[36][41]. - The Group successfully signed the irradiation station project of Bangladesh Nuclear Agricultural Research Institute in 2024, marking the first overseas government agency irradiation station and the first overseas EPC project[140]. - The overall supply project of nuclear medical equipment in Nigeria was successfully signed, representing the first successful implementation of the Group's overall nuclear medical equipment supply project[140]. - The Group improved its layout in the ASEAN market with the successful export of cold medicine supporting radiopharmaceuticals to Thailand, contributing to new growth in export revenue[140]. Corporate Governance and Changes - The company appointed Mr. Han Yongjiang as the Chairman of the Strategy Committee on September 25, 2024[19]. - The company reported a resignation of Mr. Chen Shoulei from the Audit and Risk Management Committee on June 14, 2024, due to a change in work arrangement[17]. - The company experienced the unfortunate passing of Mr. Tian Jiahe on July 21, 2024, due to illness[19]. - The company reported the resignation of Ms. Liu Xiuhong from the Remuneration and Appraisal Committee on March 28, 2025, due to a change in work arrangement[18]. Social Responsibility and Community Engagement - Over 700 public welfare activities were conducted during the reporting period, demonstrating the company's commitment to social responsibility[114]. - The Group is committed to enhancing nuclear medicine's role in diagnosing and treating major diseases, contributing to the "Healthy China" initiative[200]. - The Group's focus on quality has resulted in multiple national awards for quality control groups and trustworthy teams[197]. Technological Advancements - The company has entered the high-end radiotherapy equipment market in collaboration with U.S. Accuray, focusing on advanced technologies such as spiral tomography systems and radiosurgery robots[8]. - The world's first spiral tomotherapy system, Tomo C, was officially completed and delivered from CNNC Accuray's Tianjin plant on June 25, 2024[49]. - The Precision treatment planning system for the Tomo C was approved by the National Medical Products Administration on June 5, 2024, providing a comprehensive treatment planning solution[62]. - The Group's digital transformation initiatives include real-time data collection and analysis of key equipment, aimed at optimizing operational processes[167]. Industry Trends and Future Outlook - By 2023, the direct economic output value of China's nuclear technology application industry was approximately RMB240 billion, with an industry scale of about RMB540 billion, maintaining a growth rate of 15% to 20% for several consecutive years[102][104]. - The Three-Year Action Plan for the High-Quality Development of Nuclear Technology Application Industry (2024-2026) aims for the annual direct economic output value to reach RMB400 billion by 2026, indicating strong future growth prospects[102][104]. - The nuclear technology application industry aligns with national strategies such as Healthy China and is supported by various government initiatives aimed at enhancing public health and medical technology[100][101].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical sector [1]. Core Insights - The commercialization of nuclear medicine is accelerating, with significant growth in diagnostic nuclear drugs and the potential for domestic nuclear drugs to reach a commercialization inflection point [3][17]. - The report highlights the successful commercialization of Pluvicto and Lutathera, which are expected to generate substantial revenues, with Pluvicto projected to exceed $5 billion in peak sales [3][12]. - The report emphasizes the similarities between Radioligand Therapy (RDC) and Antibody-Drug Conjugates (ADC), suggesting that RDC could replicate the success of ADC in the market [3][22]. Summary by Sections Part 1: Overseas Nuclear Drug Rapid Growth, Domestic Commercialization Period - Overseas nuclear drugs are experiencing rapid commercialization, with Pluvicto achieving $1.392 billion in revenue in 2024, a 42% increase, and Lutathera generating $724 million, a 20% increase [3][12]. - The combined revenue from these two drugs for Novartis reached $2.116 billion, indicating the ongoing value realization of nuclear drugs [3][12]. - The report notes that the domestic nuclear drug market is set to expand significantly, with five new nuclear drugs approved since 2020, including Yttrium-90 microspheres from Yuan Da Pharmaceutical, which is expected to generate nearly HKD 500 million in revenue in 2024, a growth rate exceeding 140% [3][20]. Part 2: RDC Expected to Replicate ADC Success Path - RDC shares structural and mechanistic similarities with ADC, consisting of a targeting ligand, a linker, and a radioactive nuclide [3][22]. - The report outlines that both RDC and ADC have followed similar validation timelines, with ADC gaining market traction after the success of Enhertu, while RDC is now gaining attention following the success of Pluvicto [3][22]. - The market for new nuclear drugs is projected to reach approximately $4-5 billion in 2024, comparable to the ADC market size around 2021 [3][22]. Part 3: Domestic Nuclear Drug Pipeline Overview - The report details the current pipeline of domestic nuclear drugs, with three products in the NDA stage, including Novartis's PSMA diagnostic and therapeutic drugs [3][49]. - The leading targets in domestic research remain PSMA, FAP, and SSTR, with companies like Yuan Da Pharmaceutical and Xiantong Pharmaceutical leading in clinical project numbers [3][53]. - The anticipated approval of Novartis's two PSMA-targeted products in Q2 2025 is expected to further stimulate the domestic nuclear medicine market [3][20].

本公司综合考虑了历史因素、市场条件、资源条件及中核集团"整体•协同"的要求，订立《增资协 议》，引入战略投资者筹集资金，所募集资金将全部用于补充四川同源放射源研发生产基地项目的项目 建设及经营资金，有利于四川同源保持合理的资产负债结构。 同时，订立《增资协议》，有助于利用股东各自研发和生产优势，实现资源共享，加速推动放射源原料 国产化，为四川同源构建稳定的原料供应渠道，有助于发挥四〇四成都及成都核总的产业协同发展效 应，符合本公司及股东的整体利益。 智通财经APP讯，中国同辐(01763)发布公告，本公司附属公司中核高通于2025年3月28日与四〇四成 都、成都核总及四川同源订立《增资协议》。四〇四成都及成都核总同意以货币进行出资，对中核高通 全资附属公司四川同源分别增资人民币1234.57万元及人民币1111.11万元。增资完成后，四川同源的注 册资本将由人民币1亿元增加至人民币1.23亿元，中核高通、四〇四成都及成都核总将分别持有四川同 源81%、10%及9%的股权，四川同源将仍为中核高通(本公司附属公司)的附属公司。 四川同源成立于2019年5月，是由中核高通出资建设的对标国际一流的放射源研发生产基地。 ...

Financial Performance - The total revenue for the year ended December 31, 2024, was RMB 7,574,756,000, representing an increase of 14.2% compared to RMB 6,634,992,000 in 2023[4] - Gross profit for the same period was RMB 3,682,832,000, up from RMB 3,482,239,000, indicating a growth of 5.7%[4] - Operating profit increased to RMB 1,086,382,000, a rise of 15.3% from RMB 941,598,000 in the previous year[4] - Net profit for the year was RMB 879,537,000, compared to RMB 776,130,000 in 2023, marking an increase of 13.3%[4] - Basic and diluted earnings per share rose to RMB 1.27 from RMB 1.16, reflecting a growth of 9.5%[4] Assets and Liabilities - Non-current assets increased to RMB 5,849,059,000 from RMB 4,997,241,000, a growth of 17.1%[6] - The company's total assets less current liabilities reached RMB 9,743,980,000, up from RMB 8,937,789,000, indicating an increase of 9.0%[6] - The total equity attributable to shareholders increased to RMB 5,005,301,000 from RMB 4,693,320,000, representing a growth of 6.6%[7] - Trade receivables as of December 31, 2024, totaled RMB 5,155,122,000, an increase of 26.4% from RMB 4,080,997,000 in 2023[30] - Current assets decreased slightly by 1.2% from RMB 3,940.5 million in 2023 to RMB 3,894.9 million in 2024, mainly due to a reduction in cash and an increase in bank loans[98] Revenue Breakdown - The revenue from radiopharmaceutical sales was RMB 4,167,606,000 in 2024, up from RMB 4,017,476,000 in 2023, reflecting a growth of 3.7%[14] - The revenue from nuclear medical equipment sales increased to RMB 912,477,000 in 2024, compared to RMB 706,124,000 in 2023, marking a growth of 29.2%[14] - The group’s revenue from technical services rose to RMB 552,522,000 in 2024, up from RMB 349,390,000 in 2023, representing an increase of 58.2%[14] - The revenue from irradiation services was RMB 172,788,000 in 2024, compared to RMB 161,687,000 in 2023, showing a growth of 6.9%[14] - The group’s revenue from medical device sales increased to RMB 801,650,000 in 2024, up from RMB 544,690,000 in 2023, reflecting a growth of 47.0%[14] Expenses and Costs - Total other income for 2024 was RMB 77,518,000, a significant decrease of 67.8% compared to RMB 240,928,000 in 2023[23] - Total employee costs for 2024 were RMB 886,024,000, up from RMB 867,378,000 in 2023, reflecting a rise of 2.0%[25] - Sales cost rose by 23.4% from RMB 3,152.8 million in 2023 to RMB 3,891.9 million in 2024, primarily due to increased sales costs in nuclear medical equipment and related services[86] - Administrative expenses, R&D costs, and credit impairment losses increased by 3.7% from RMB 1,013.2 million in 2023 to RMB 1,050.3 million in 2024, while the percentage of these costs to revenue decreased from 15.3% to 13.9%[90] - Financial expenses grew by 34.0% from RMB 36.1 million in 2023 to RMB 48.4 million in 2024, primarily due to increased external borrowing for funding needs[91] Dividends and Shareholder Information - The company proposed a final dividend of RMB 0.309 per share for 2024, slightly down from RMB 0.3131 per share in 2023[29] - The expected payment date for the final dividend is before August 2, 2025[131] - Shareholders listed on June 12, 2025, will receive the final dividend for the fiscal year 2024, pending approval at the annual meeting[134] Research and Development - Research and development expenses were RMB 300,286,000, slightly down from RMB 306,051,000 in 2023, showing a decrease of 1.5%[4] - The group applied for 274 patents and obtained 224 patent grants during the reporting period, enhancing its technological capabilities[48] - The company has a talent pool of 507 R&D personnel, including 1 foreign expert, 9 national-level talents, and 11 provincial-level talents, focusing on production technology optimization and new product development[58] Market Expansion and Collaborations - The group is actively expanding its international market presence, participating in various global industry conferences to enhance brand recognition[46] - The company is committed to supporting the "Healthy China" strategy by providing comprehensive solutions for nuclear medicine and radiation therapy[65] - The company is actively pursuing international collaborations and expanding its product offerings in the nuclear medicine sector, including the introduction of new isotopes[42] Corporate Governance and Compliance - The company has complied with the Corporate Governance Code and has established a modern corporate governance framework[124] - The Audit and Risk Management Committee has reviewed the consolidated financial results for the year ending December 31, 2024[126] - The company has not disclosed any significant adverse changes in its financial and operational conditions as of December 31, 2024[111]

88ENNE 中期報告 2024 Interim Report 中國同輻股份有限公司 China Isotope & Radiation Corporation （於中華人民共和國註冊成立的股份有限公司） (A joint stock company incorporated in the People's Republic of China with limited liability) 股份代號 Stock Code：1763 注射用亚缘亚甲基二路B C =7 == 2024 中期報告 Interim Report 目 錄 公司資料 2 財務摘要 4 集團簡介 5 管理層討論與分析 6 企業管治報告及其他資料 32 簡明合併中期財務資料之審閱報告 38 簡明合併損益表 39 簡明合併損益及其他全面收入表 40 簡明合併財務狀況表 41 簡明合併權益變動表 43 簡明合併現金流量表 45 簡明合併中期財務報告附註 46 釋義 69 2 中國同輻股份有限公司 公司資料 | --- | --- | |------------------------------------------------------|- ...

Financial Performance - Revenue for the six months ended June 30, 2024, was RMB 2,810,279 thousand, an increase of 2.6% compared to RMB 2,739,483 thousand for the same period in 2023[2] - Gross profit for the same period was RMB 1,464,150 thousand, slightly down from RMB 1,485,483 thousand, resulting in a gross margin of approximately 52.1%[2] - Operating profit increased to RMB 409,429 thousand, representing a growth of 20.5% from RMB 339,708 thousand in the previous year[2] - Profit for the period attributable to equity shareholders was RMB 154,496 thousand, up 23.2% from RMB 125,413 thousand in the prior year[2] - Basic and diluted earnings per share rose to RMB 0.48, compared to RMB 0.39 for the same period last year, reflecting a 23.1% increase[2] - Total comprehensive income increase of RMB 729,000 for the period, with contributions of RMB 552,000 from equity shareholders and RMB 177,000 from non-controlling interests[12] - Basic and diluted earnings per share increased to RMB 0.400 after accounting policy adjustments, up from RMB 0.398[11] - For the first half of 2024, the company achieved revenue of RMB 2,810.3 million, a year-on-year increase of 2.6%, and a net profit of RMB 306.7 million, up 8.7%[37] Assets and Liabilities - Total assets as of June 30, 2024, amounted to RMB 8,479,589 thousand, an increase from RMB 8,194,469 thousand at the end of 2023[4] - Non-current assets increased to RMB 5,262,997 thousand from RMB 4,997,241 thousand, indicating a growth of 5.3%[4] - Current liabilities rose to RMB 4,414,399 thousand, compared to RMB 4,253,921 thousand at the end of 2023, reflecting an increase of 3.8%[5] - The company reported a net cash position of RMB 2,723,263 thousand, down from RMB 2,891,624 thousand at the end of 2023[4] - The company's trade receivables as of June 30, 2024, amounted to RMB 3,998,300,000, an increase from RMB 3,876,341,000 as of December 31, 2023[32] - The company's cash and cash equivalents as of June 30, 2024, totaled RMB 2,723,263,000, a decrease from RMB 2,891,624,000 as of December 31, 2023[34] Revenue Segments - Pharmaceutical sales generated RMB 1,767,944,000, a slight decrease of 1.1% from RMB 1,787,803,000 in 2023[15] - Revenue from radiation source products increased by 14.7% to RMB 233,247,000, compared to RMB 203,321,000 in 2023[15] - The revenue from the radiation source products segment reached RMB 256.9 million, reflecting a year-on-year growth of 15.0%, driven by increased market demand due to the recovery of the nuclear power industry[41] - The revenue from radiation therapy equipment and related services for the reporting period was RMB 273.8 million, a year-on-year decrease of 31.9% due to delayed certification of the new product Tomo C and reduced sales of older products[44] - The trade services and other businesses generated revenue of RMB 425.2 million, representing a year-on-year increase of 72.8%, primarily driven by the newly acquired industrial testing services and increased sales of isotopes and exported medical equipment[45] Investments and Acquisitions - The company acquired 100% equity of Dalian Nuclear Radiation Technology Co., Ltd. for RMB 4,611,000, making it a subsidiary[9] - As of June 30, 2024, the company has invested RMB 410.4 million in the Tongfu Fund, which has a total paid-in capital of RMB 910.4 million, representing a 45.1% ownership stake[58] - The net assets of the Tongfu Fund, measured at fair value, amount to RMB 1,011.9 million, with the company's share valued at RMB 456.4 million, accounting for 3.3% of the company's total assets[58] - The company plans to utilize the remaining funds from the IPO for various projects, including the establishment of production and distribution subsidiaries and new production facilities[94] Research and Development - The company has launched the first smart nuclear medicine overall solution and the "Radiation Intelligence 1.0" management system, establishing the world's first national-level smart nuclear medicine demonstration center[47] - Multiple radiopharmaceuticals are in various stages of development, including sodium fluoride injection, which has completed clinical trials and submitted for market registration[48] - The group has developed a PET imaging agent, [18F] Florbetazine, for early diagnosis of Alzheimer's disease, which received clinical trial approval on March 8, 2023, and has completed Phase I clinical trials[50] - The group is advancing the development of 6-[18F] Fluoro-L-DOPA for diagnosing Parkinson's disease, with Phase III clinical trials expected to start following its approval on April 17, 2023[50] Market Expansion and Strategy - The company is focused on expanding its market presence and investing in new technologies, although specific figures or timelines were not disclosed in the report[6] - The company plans to continue expanding its product lines and services, particularly in the pharmaceutical and radiation sectors, to drive future growth[16] - The company is actively pursuing international collaborations to introduce advanced radiopharmaceuticals and enhance medical device trade sales[45] - The company aims to achieve a new high in operating revenue and net profit in 2024, driven by favorable policies and a recovering market demand[64] Compliance and Governance - The company has adopted the corporate governance code and has complied with its mandatory provisions during the reporting period[98] - The audit and risk management committee consists of two independent non-executive directors and one non-executive director, ensuring compliance with listing rules[100] - The group has established policies to monitor credit risk and assess the credit quality of new customers before accepting requests exceeding certain credit limits[87] Employee and Operational Metrics - As of June 30, 2024, the company employed 3,132 employees, a decrease from 3,264 employees as of June 30, 2023[95] - Employee costs for the six months ended June 30, 2024, were approximately RMB 378.5 million, compared to RMB 361.0 million for the same period in 2023[95] - The company has a commitment to provide training and development opportunities for employees to enhance their skills and career growth[95]

Financial Performance - Revenue for the year ended December 31, 2023, was RMB 6,634,992 thousand, representing an increase from RMB 6,153,549 thousand in 2022, a growth of approximately 7.8%[8] - Gross profit for 2023 was RMB 3,482,239 thousand, with a gross margin of 52.5%, down from a gross margin of 57.2% in 2022[8] - Operating profit increased to RMB 941,598 thousand, with an operating profit margin of 14.2%, compared to 14.9% in the previous year[8] - Net profit attributable to equity shareholders was RMB 370,967 thousand, with basic earnings per share of RMB 1.16, down from RMB 1.23 in 2022[8] - The net profit for the year was RMB 778 million, reflecting a year-on-year increase of 2.8%[23] - The company reported a total asset value of RMB 13.19 billion and a net asset value of RMB 7.14 billion, with a debt-to-asset ratio of 45.9%[23] - The company’s net profit attributable to shareholders was RMB 371 million, which represents a year-on-year decline of 5.43%[23] - Revenue increased by 7.82% from RMB 6,153.5 million in 2022 to RMB 6,635.0 million in 2023, driven by growth in pharmaceuticals and radiation therapy equipment[101] - Sales cost rose by 19.6% from RMB 2,635.9 million in 2022 to RMB 3,152.8 million in 2023, primarily due to increased costs in radiation therapy equipment and related services[102] - Gross profit decreased by 1.0% from RMB 3,517.7 million in 2022 to RMB 3,482.2 million in 2023, with gross margin declining from 57.2% to 52.5%[102] Assets and Liabilities - Total assets as of December 31, 2023, were RMB 13,191,710 thousand, an increase from RMB 11,789,723 thousand in 2022[8] - Total liabilities increased to RMB 6,052,382 thousand from RMB 5,180,115 thousand in 2022[8] - Current assets increased by 8.7% from RMB 7,543.8 million in 2022 to RMB 8,194.5 million in 2023, with a notable rise in trade receivables[117] - Current asset net worth grew by 12.2% from RMB 3,512.4 million in 2022 to RMB 3,940.5 million in 2023[117] - Trade and other receivables amounted to RMB 4,130.9 million, with a provision for bad debts of RMB 217.82 million[120] - Trade and other payables totaled RMB 3,882.6 million as of December 31, 2023[121] - The total bank loans of the group reached RMB 1,570.37 million as of December 31, 2023[122] Research and Development - Research and development investment intensity exceeded 9%, with nearly 300 patents applied for, marking a 55% increase year-on-year[14] - The company has multiple radiopharmaceuticals in various stages of research and development, including [18F] sodium fluoride injection, which has completed clinical trials and submitted for market registration[41] - The [131I]-MIBG injection for diagnosing neuroendocrine tumors is currently undergoing Phase III clinical trials[43] - The company has filed 298 patent applications and received 240 patent grants, enhancing its technological capabilities[47] - The company has 945 valid patents, including 149 invention patents, reflecting its strong R&D capabilities[47] Market and Segment Performance - The company generated 62.2% of its revenue and 83.0% of its gross profit from the pharmaceutical segment, indicating a strong reliance on this high-potential industry[11] - The pharmaceutical segment achieved revenue of RMB 4,128.6 million, a year-on-year increase of 5.2%[26] - Revenue from diagnostic and therapeutic radioactive drugs reached RMB 1,682.8 million, up 15.3% year-on-year[26] - The breath testing segment generated revenue of RMB 2,323.8 million, a decline of 1.0% year-on-year[26] - The radiation source products segment reported revenue of RMB 586.2 million, a year-on-year increase of 0.9%[28] - The nuclear medical equipment and related services segment saw revenue of RMB 933.7 million, a significant increase of 27.5% year-on-year[33] - The trade services and other businesses generated revenue of RMB 815.7 million, reflecting a year-on-year growth of 9.3%[36] Strategic Initiatives and Collaborations - The company plans to leverage its collaboration with China National Nuclear Corporation to enhance its capabilities in isotope and radiopharmaceutical applications[11] - Future market demand for nuclear technology applications is expected to grow, providing broader development opportunities for the company[10] - The company accelerated the development of the "One County, One Specialty" initiative in collaboration with the Wu Jieping Medical Foundation[17] - The company has established a technology innovation committee to enhance its innovation-driven development strategy[18] - The company is focusing on the domestic Lu-177 and Ge/Ga generator markets to establish a foundation for future growth in 2024[39] - The company is actively expanding its market presence through various academic and promotional events, enhancing its brand recognition[38] Corporate Governance and Management - The board confirmed that there were no significant adverse changes in the financial and operational conditions as of December 31, 2023[139] - The board consists of 11 members, including 3 executive directors and 4 independent non-executive directors, ensuring a balanced composition for effective decision-making[166] - The company has adopted the principles and code provisions of the Corporate Governance Code as its governance framework[160] - The board regularly reviews the contributions of directors to ensure they fulfill their responsibilities adequately[165] - The company has established six committees, including the Audit and Risk Management Committee and the Strategic Committee, to oversee specific aspects of the company's affairs[186] Future Outlook - In 2024, the company aims to achieve new highs in operating revenue and net profit, focusing on maintaining strong growth momentum[83] - The company plans to accelerate the construction of six major bases in North China, East China, and Sichuan to enhance its industry control capabilities[83] - The company aims to improve management efficiency through digital transformation and the establishment of smart factory projects[87] - The company recognizes the "14th Five-Year Plan" as a strategic opportunity period for the nuclear technology application industry and is committed to achieving its key tasks[90]

Financial Performance - For the year ended December 31, 2023, the total revenue was RMB 6,634,992 thousand, an increase of 7.8% compared to RMB 6,153,549 thousand in 2022[2] - The gross profit for 2023 was RMB 3,482,239 thousand, slightly down from RMB 3,517,682 thousand in 2022, resulting in a gross margin of approximately 52.5%[2] - Operating profit increased to RMB 941,598 thousand in 2023, up from RMB 913,963 thousand in 2022, reflecting a growth of 3.0%[2] - The net profit for the year was RMB 776,130 thousand, representing a 2.8% increase from RMB 755,237 thousand in 2022[2] - Basic and diluted earnings per share for 2023 were RMB 1.16, compared to RMB 1.23 in 2022, indicating a decrease of 5.7%[2] - Total comprehensive income for the year was RMB 770,324 thousand, slightly up from RMB 767,386 thousand in 2022[4] Assets and Liabilities - Non-current assets as of December 31, 2023, amounted to RMB 3,601,172 thousand, an increase from RMB 2,939,823 thousand in 2022[5] - Current assets increased to RMB 4,997,241 thousand in 2023 from RMB 4,245,880 thousand in 2022, showing a growth of 17.7%[5] - Total liabilities as of December 31, 2023, were RMB 8,194,469 thousand, compared to RMB 7,543,843 thousand in 2022, reflecting an increase of 8.7%[5] - The company's equity attributable to shareholders was RMB 4,693,320 thousand as of December 31, 2023, up from RMB 4,468,659 thousand in 2022, indicating a growth of 5.0%[6] Revenue Breakdown - Pharmaceutical sales generated RMB 4,017,476 thousand in 2023, up from RMB 3,880,262 thousand in 2022, reflecting a growth of 3.5%[16] - Revenue from medical devices surged to RMB 544,690 thousand in 2023, compared to RMB 171,843 thousand in 2022, marking a significant increase of 216.5%[16] - The report indicates that external customer revenue for the radiation therapy equipment and related services segment was RMB 706,406 thousand in 2023, compared to RMB 514,012 thousand in 2022, representing a growth of 37.5%[22] - Revenue from the sale of subsidiaries amounted to RMB 158,435 thousand in 2023, with no comparable figure in 2022[25] Expenses and Costs - Employee costs rose to RMB 867.378 million in 2023, up from RMB 797.833 million in 2022, reflecting an increase of 8.69%[27] - Depreciation expenses increased to RMB 237.104 million for property, plant, and equipment, compared to RMB 204.937 million in 2022, marking a growth of 15.66%[28] - Sales cost rose by 19.6% from RMB 2,635.9 million in 2022 to RMB 3,152.8 million in 2023, primarily due to increased costs in radiation therapy equipment and related services[79] - Administrative expenses, R&D costs, and credit impairment losses increased by 11.7% from RMB 906.9 million in 2022 to RMB 1,013.2 million in 2023, representing 15.3% of revenue[82] Strategic Acquisitions and Partnerships - The company acquired 100% equity of Dalian China Nuclear Radiation Technology Co., Ltd. for a total consideration of RMB 4,611,000[9] - The company is focused on expanding its market presence through strategic acquisitions and partnerships in the radiation technology sector[9] - The company signed agreements to acquire two enterprises with a total investment amount of RMB 103.4087 million, including Dalian CNNC Radiation Technology Co., Ltd. for RMB 4.6105 million and Xi'an Zhanshi Testing Engineering Co., Ltd. for RMB 98.7982 million[56] Research and Development - The company has multiple radiopharmaceuticals in various stages of research and development, including the completion of clinical trials for Fluorine-18 Sodium Injection and ongoing Phase III trials for Iodine-131 MIBG Injection[47] - The company has received clinical trial approval for Fluorine-18 Beta-Amyloid Injection, which is being developed for early diagnosis of Alzheimer's disease and is currently in Phase I trials[49] - The company has established research cooperation with several prestigious institutions, including the Chinese Academy of Sciences and Harbin Institute of Technology, to enhance academic exchange and talent cultivation[54] Market Expansion and International Presence - The company is actively expanding its international market presence, successfully signing a nuclear medicine project in Indonesia and winning a large foreign aid medical project in Uzbekistan[55] - The company is focusing on the domestic Lu-177 and Ge/Ga generator market to establish a foundation for market expansion in 2024[46] Corporate Governance and Compliance - The group has adopted a corporate governance code and has complied with its mandatory provisions throughout the reporting period[102] - The audit and risk management committee reviewed and confirmed the group's consolidated financial performance for the year ended December 31, 2023[104] Future Outlook - In 2024, the company aims to achieve new highs in operating revenue and net profit, focusing on maintaining strong growth momentum[67] - The company is committed to deepening reforms to release innovation vitality and development potential, with a focus on strategic emerging industries[68]

Financial Performance - Revenue for the six months ended June 30, 2023, was RMB 2,740.6 million, an increase of 4.6% from RMB 2,619.6 million for the same period in 2022[6] - Gross profit for the same period was RMB 1,484.8 million, with a gross margin of 54.2%, down from 58.5% in the previous year[6] - Operating profit increased to RMB 340.8 million, maintaining an operating profit margin of 12.4%[6] - Profit attributable to equity shareholders was RMB 126.9 million, representing a 13.8% increase from RMB 112.0 million in the prior year[6] - Net profit for the same period was RMB 283.7 million, representing a year-on-year growth of 17.9%[10] - Revenue from the pharmaceutical segment reached RMB 1,787.8 million, up 1.3% year-on-year, with diagnostic and therapeutic radioactive drugs contributing RMB 816.6 million, a 15.9% increase[12] - Revenue from radiation therapy equipment and related services surged to RMB 402.1 million, marking a 49.3% increase compared to the previous year[15] - Revenue increased by 4.6% from RMB 2,619.6 million to RMB 2,740.6 million, driven by significant growth in the radiation source and radiation therapy equipment segments[45] Assets and Liabilities - Total assets as of June 30, 2023, were RMB 11,796.8 million, compared to RMB 11,686.6 million at the end of 2022[7] - Total liabilities increased to RMB 5,301.3 million from RMB 5,133.1 million at the end of 2022[7] - Current assets decreased by 4.0% from RMB 3,524.9 million to RMB 3,383.2 million, mainly due to a reduction in cash and cash equivalents[55] - Trade receivables and other receivables amounted to RMB 4,379.9 million, with a provision for bad debts of RMB 207.9 million as of June 30, 2023[60] - Trade and other payables totaled RMB 3,812.2 million as of June 30, 2023[61] - As of June 30, 2023, the total bank loans of the group amounted to RMB 946.7 million[62] Market Position and Strategy - The company generated 65.23% of its revenue and 84.55% of its gross profit from the pharmaceutical segment, indicating a strong focus on nuclear medicine[8] - The company is positioned as a leading manufacturer in the domestic market for diagnostic and therapeutic radioactive pharmaceuticals, with significant market potential[8] - Future market demand for nuclear technology applications is expected to grow, driven by economic development and improved living standards in China[8] - The company plans to leverage its collaboration with China National Nuclear Corporation to enhance its service offerings and market reach[8] - The company is actively expanding its market presence through strategic collaborations and product integration in the radioactive pharmaceuticals sector[11] - The company is focusing on enhancing its academic brand in respiratory testing products and promoting health management knowledge nationwide[11] Research and Development - The company has established a special fund for smart nuclear medicine in collaboration with the Wu Jieping Medical Foundation, aiming to create integrated solutions in the nuclear medicine field[18] - As of June 30, 2023, the company has multiple radiopharmaceuticals in various stages of development, including [18F] sodium fluoride injection, which has completed clinical trials and submitted for market registration[19] - The company is conducting a Phase III clinical trial for [131I]-MIBG injection, which is used for diagnosing neuroendocrine tumors[20] - The company has received approval for clinical trials of [18F] Florastamin injection, a promising prostate cancer diagnostic drug, in March 2023[20] - The company is advancing the development of [103Pd] sealed seed sources for prostate cancer treatment, having completed all preclinical research[22] - The company is actively promoting the standardization of nuclear medicine treatment guidelines and the establishment of more demonstration bases in Zhejiang Province[18] Operational Efficiency - The company aims to achieve new highs in operating income and net profit for the full year of 2023, driven by favorable macroeconomic conditions and technological innovation[34] - The company is committed to enhancing its internal management systems to support its international operations and improve economic efficiency[29] - The company is focusing on enhancing its core competitiveness through innovation-driven development and has established a Science and Technology Innovation Committee to lead these efforts[32] - The company has achieved significant progress in the construction of its isotope production base, which will become the largest in the country upon completion[31] Financial Management - The company has sufficient cash reserves and committed funding from major financial institutions to meet short-term and long-term liquidity needs[67] - The group has established policies to monitor credit risk continuously, focusing on the credit quality of new customers before accepting credit requests[66] - The company is actively monitoring market risks, including foreign exchange and liquidity risks, to ensure financial stability[39][41] - The company will continue to strengthen its compliance system and improve risk management efficiency to mitigate operational risks[42] Shareholder Information - The board does not recommend the payment of an interim dividend for the six months ended June 30, 2023[69] - The company has a total share capital of RMB 319,874,900, consisting of 79,968,800 H shares and 239,906,100 domestic shares[82] - As of June 30, 2023, the major shareholder China National Nuclear Corporation holds 236,150,233 shares, representing 98.43% of the beneficial ownership in domestic shares[85] - The total beneficial ownership of China National Nuclear Corporation and its subsidiaries in domestic shares is approximately 98.43%[86] Employee and Operational Metrics - Employee costs for the six months ended June 30, 2023, were approximately RMB 357.6 million, a decrease from RMB 485.9 million for the same period in 2022[73] - The company employed 3,264 employees as of June 30, 2023, compared to 3,244 employees as of June 30, 2022[73] - The company’s employee compensation policy aims to incentivize and retain talented employees to achieve long-term corporate goals[73]